PMK 075 Tab Allergy
Natural health product licensed in Canada
- Licence holder
- PMK Federal Regulatory Consultants Ltd.
- NPN or DIN-HM
- 80038821
- Status
- Inactive licence
- Licence date
- 17 January 2013
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Urtica dioica L.: L'étiquetage des compléments alimentaires contenant les parties souterraines de cette plante doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Urtica dioica Source : Sommité Extraction ratio : 4:1 Dry plant equivalent : 1,200 mg | 300 mg | Not calculated |
Non-medicinal ingredients
Eau purifiée, Dioxyde de silicium, Acide stéarique, Stéarate de magnésium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | minimum: 1 day ; maximum: 3 days |
Uses authorised in Canada
Used as a decongestant/ to relieve nasal congestion. Used as a decongestant/ to relieve nasal congestion due to hay fever or allergies. Used in Herbal Medicine to help relieve seasonal allergy symptoms.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are pregnant or breastfeeding. Do not use if you are taking, or have taken in the past two weeks monoamine oxidase (MAO) inhibitors.
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking medication and/or natural health products for allergy symptoms, asthma, cough or cold, or weight control. Consult a healthcare practitioner prior to use if you are taking other products which contain caffeine, ephedrine, phenylpropanolamine or pseudoephedrine. Consult a health care practitioner prior to use if you have glaucoma, seizure disorders, cardiovascular disease, diabetes, difficulty in urination due to prostate enlargement, pre-existing psychiatric conditions or thyroid problems. Keep out of reach of children.
- Effets indésirables connus
Insomnia and rapid heartbeat have been known to occur; in which case, discontinue use. Restlessness, irritability, dizziness, tremor, severe headache, insomnia, loss of appetite, nausea, rapid heartbeat, shortness of breath and/or disturbance of urination have been known to occur; in which case, discontinue use.
Source
Official Health Canada record, licence 80038821
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.